An attempt to assess the replacement dose of human growth hormone in the treatment of growth hormone deficient children.
In 25 patients with hGH deficiency, who had been treated long-term with hGH, the mode of hGH administration was switched from the conventional method (0.3-0.5 IU/kg/week, in two or three divided doses, intramuscularly) to daily subcutaneous injection at 1900-2100 hours with a dose of 0.46 +/- 0.07 IU/kg/week (equivalent to 14.7 +/- 2.0 IU/m2/week). After 1-3 months of this new mode of hGH administration, blood and urine were sampled at 0900 hours after overnight fasting. Blood glucose, plasma insulin, plasma IGF-1 and plasma total IGF (after extraction) were analysed in blood samples. IGF-1 and hGH were measured in urine samples. These measurements indicated that the dose studied was close to a replacement one, but might be slightly higher than the exact replacement dose.
Hibi
I
I
National Children's Medical Research Centre, Tokyo, Japan.
Tanaka
T
T
Yano
H
H
Umezawa
S
S
Kagawa
J
J
Tanae
A
A
Ishikawa
E
E
D000293:Adolescent; D002648:Child; D004334:Drug Administration Schedule; D006130:Growth Disorders / Q000188:drug therapy*; D013006:Growth Hormone / Q000008:administration & dosage / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000097:blood; D013997:Time Factors
D007328:Insulin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone